Translational biology approach to identify causative factors for rare toxicities in humans and animals.
Genome-wide RNA splicing (with gene expression) can be used to discover variations that drive specific diseases and / or change the susceptibility in individuals to drug responses including tissue specific toxicities. Evidence linking causative SNPs to individual splicing differences between individuals is emerging and this may lead to a better understanding of susceptibilities related to rare drug-induced toxicities. The development of more sensitive genomics tools is expected to further the study of variations in molecular phenotype from alternative splicing of pre-mRNA. This report highlights a genomics platform developed to measure splicing changes that occur in response to drug exposures, and therefore is applicable for the study of drug-induced toxicity. The platform is applicable for humans, all toxicology species, and specialized model systems. For efficiency, multiple samples can be combined into a single sequencing run and individual sequences can be separated via informatics. Biobanked specimens from clinical trials, toxicology studies, from commercial sources, and/or from public 'omics' data resources such as in NCBI are the only sample or non-sample data requirements.
Emiliem, Inc., Emeryville,CA 94608, USA. dale@emiliem.com
E Dale
ED
Johnson
Sucha
S
Sudarsanam
Jonathan
J
Bingham
Subha
S
Srinivasan
D017398:Alternative Splicing / Q000187:drug effects; D000818:Animals; D019295:Computational Biology / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D020224:Expressed Sequence Tags; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study; D023281:Genomics / Q000379:methods; D006801:Humans; D057170:Translational Research, Biomedical / Q000379:methods*